- Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related droolingGiovanni Lagalla
Clinica Neurologica, Dipartimento di Neuroscienze, Universita Politecnica delle Marche, Ospedali Riuniti, Ancona, Italy
J Neurol 256:563-7. 2009..To investigate the safety, efficacy and effectiveness of botulinum toxin type-B (BTX-B) injections into the parotid glands to reduce drooling in Parkinson's disease (PD) subjects...
- Familial hemifacial spasm and determinants of late onsetGiovanni Lagalla
Clinica Neurologica, Dipartimento di Scienze Neurologiche, Az Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca 1, 60020, Ancona, Italy
Neurol Sci 31:17-22. 2010..The distribution of NVC in several members of the same family suggests a genetic susceptibility towards vascular anomaly...
- Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled studyGiovanni Lagalla
Clinica di Neuroriabilitazione, Dipartimento di Neuroscienze, Universita Politecnica delle Marche, Az Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy
Mov Disord 21:704-7. 2006..01), as well as in saliva production (Time x Group effect: P<0.0001). No adverse events were recorded. BoNTX injections are safe and effective treatment for the management of PD-related drooling...